Labcorp LH
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Labcorp (LH) Business Model and Operations Summary
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Key Insights
Labcorp (LH) Core Market Data and Business Metrics
Latest Closing Price
$232.65Market Cap
$19.48 BillionPrice-Earnings Ratio
26.32Total Outstanding Shares
83.70 Million SharesTotal Employees
70,000Dividend
$0.72 Per Share QuarterlyIPO Date
April 24, 1991SIC Description
Services-medical LaboratoriesPrimary Exchange
New York Stock ExchangeHeadquarters
358 S Main St, Burlington, NC, 27215
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow | $981.90 Million |
| Net Cash Flow From Operating Activities | $1.59 Billion |
| Net Cash Flow From Financing Activities, Continuing | $779.90 Million |
| Exchange Gains/Losses | $-17 Million |
| Net Cash Flow From Investing Activities | $-1.37 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-1.37 Billion |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Revenues | $13.01 Billion |
| Other Operating Expenses | $307.70 Million |
| Operating Income/Loss | $1.09 Billion |
| Benefits Costs and Expenses | $0 |
| Cost Of Revenue | $9.38 Billion |
| Operating Expenses | $2.54 Billion |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $-202.30 Million |
| Comprehensive Income/Loss | $544.80 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $1.10 Million |
| Comprehensive Income/Loss Attributable To Parent | $543.70 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities And Equity | $18.38 Billion |
| Other Current Assets | $3.62 Billion |
| Current Liabilities | $3.33 Billion |
| Inventory | $493.20 Million |
| Other Non-current Assets | $7.04 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
Historical Dividends
Current dividend: $0.72 Per Share Quarterly
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| Jan 8, 2025 | Mar 12, 2025 | Feb 27, 2025 | $0.72 | Quarterly |
| Oct 10, 2024 | Dec 13, 2024 | Nov 26, 2024 | $0.72 | Quarterly |
| Jul 25, 2024 | Sep 13, 2024 | Aug 29, 2024 | $0.72 | Quarterly |
| Apr 11, 2024 | Jun 12, 2024 | May 28, 2024 | $0.72 | Quarterly |
| Jan 12, 2024 | Mar 13, 2024 | Feb 27, 2024 | $0.72 | Quarterly |
| Oct 12, 2023 | Dec 12, 2023 | Nov 8, 2023 | $0.72 | Quarterly |